In this interview from AAO 2015, Dr. Leah Makley describes her novel work with a sterol eye drop that binds α-crystallins, thereby improving lens transparency and potentially reversing cataract progression. Cataracts are caused by α-crytallin proteins clumping in the eye. Using a mouse model, Dr. Makley found that the experimental compound stabilized the crystallins and prevented further aggregation, suggesting the molecule could be used as both a preventive treatment and in the management of chronic cataracts.